Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals

被引：25

作者：

Bunupuradah T. ^{[1
]}

Wannachai S. ^{[1
]}

Chuamchaitrakool A. ^{[1
]}

Intasan J. ^{[1
]}

Nuchapong T. ^{[1
]}

Neiss W. ^{[2
]}

Kramm K. ^{[2
]}

Pancharoen C. ^{[3
]}

Burger D. ^{[4
]}

Ananworanich J. ^{[1
]}

机构：

[1] The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok

[2] FLAVORx Company, Bethesda, MD

[3] Chulalongkorn University, Bangkok

[4] UMC St Radboud, Nijmegen

来源：

AIDS Research and Therapy | / 3卷 / 1期

关键词：

Efavirenz; Trough Level; Final Visit; Thai Child; Crushed Tablet;

D O I：

10.1186/1742-6405-3-30

中图分类号：

学科分类号：

摘要：

We evaluated whether FLAVORx helped thirty Thai children take opened capsule, crushed tablets and liquid generic ARVs with more ease. All children had excellent adherence, evaluated by PACTG Standard International Questionnaire and interviewing, before and after one month of FLAVORx. Eighty percent took ARV with more ease and wish to continue FLAVORx. Strawberry was the most popular flavor. © 2006 Bunupuradah et al; licensee BioMed Central Ltd.

引用

共 11 条

[1]

(2006)

[2]

Guideline for the use of antiretroviral agents in pediatric HIV infection March 24, 2005, AIDSinfo, (2005)

[3]

Watson D.C., Farley J.J., Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1, Pediatr Infect Dis J, 18, pp. 682-689, (1999)

[4]

Van dyke R.B., Lee S., Johnson G.M., Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection, Peadiatrics, 109, (2002)

[5]

Tuboi S.H., Harrison L.H., Sprinz E., Albernaz R.K., Schechter M., Predictors of Virologic Failure in HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy in Porto Alegre, Brazil, J Acquir Immune Defic Syndr, 140, pp. 324-328, (2005)

[6]

Maggiolo F., Ravasio L., Ripamonti D., Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors, Clin Infect Dis, 1, pp. 158-163, (2005)

[7]

Jaderlund C., The impact of a commercially available medication flavoring system (FLAVORx©) on pediatric inpatients admitted to a children's Hospital, 14th Pediatric Pharmacy Conference: PPAG Annual Meeting, (2005)

[8]

Jaderlund C., The impact of a commercially available medication flavoring system (FLAVORx©) on pediatric inpatients admitted to a children's Hospital, J Pediatr Pharmacol Ther, 10, pp. 124-125, (2005)

[9]

(2005)

[10]

Revised classification system for human immunodeficiency virus infection in children less than 13 years of age, MMWR, 43, RR-12, pp. 1-10, (1994)

← 1 2 →